JP2020525436A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020525436A5 JP2020525436A5 JP2019570906A JP2019570906A JP2020525436A5 JP 2020525436 A5 JP2020525436 A5 JP 2020525436A5 JP 2019570906 A JP2019570906 A JP 2019570906A JP 2019570906 A JP2019570906 A JP 2019570906A JP 2020525436 A5 JP2020525436 A5 JP 2020525436A5
- Authority
- JP
- Japan
- Prior art keywords
- controlled release
- compound
- dosage form
- gastric resistance
- resistance controlled
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023147484A JP2023175778A (ja) | 2017-06-21 | 2023-09-12 | 胃耐性制御放出経口剤形 |
| JP2025101290A JP2025134828A (ja) | 2017-06-21 | 2025-06-17 | 胃耐性制御放出経口剤形 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762523204P | 2017-06-21 | 2017-06-21 | |
| US62/523,204 | 2017-06-21 | ||
| PCT/US2018/038853 WO2018237207A1 (en) | 2017-06-21 | 2018-06-21 | GESTRO-RESISTANT ORAL DOSAGE FORMS WITH CONTROLLED RELEASE |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023147484A Division JP2023175778A (ja) | 2017-06-21 | 2023-09-12 | 胃耐性制御放出経口剤形 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020525436A JP2020525436A (ja) | 2020-08-27 |
| JP2020525436A5 true JP2020525436A5 (https=) | 2021-07-29 |
Family
ID=62904624
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019570906A Pending JP2020525436A (ja) | 2017-06-21 | 2018-06-21 | 胃耐性制御放出経口剤形 |
| JP2023147484A Pending JP2023175778A (ja) | 2017-06-21 | 2023-09-12 | 胃耐性制御放出経口剤形 |
| JP2025101290A Pending JP2025134828A (ja) | 2017-06-21 | 2025-06-17 | 胃耐性制御放出経口剤形 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023147484A Pending JP2023175778A (ja) | 2017-06-21 | 2023-09-12 | 胃耐性制御放出経口剤形 |
| JP2025101290A Pending JP2025134828A (ja) | 2017-06-21 | 2025-06-17 | 胃耐性制御放出経口剤形 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US11464744B2 (https=) |
| EP (1) | EP3641732A1 (https=) |
| JP (3) | JP2020525436A (https=) |
| CN (1) | CN111511353A (https=) |
| AU (2) | AU2018290287B2 (https=) |
| BR (1) | BR112019027398A2 (https=) |
| CA (1) | CA3067031A1 (https=) |
| CL (1) | CL2019003743A1 (https=) |
| CO (1) | CO2019014496A2 (https=) |
| IL (3) | IL308650B2 (https=) |
| MX (1) | MX2023002994A (https=) |
| NZ (1) | NZ760127A (https=) |
| PE (1) | PE20200732A1 (https=) |
| UA (1) | UA127349C2 (https=) |
| WO (1) | WO2018237207A1 (https=) |
| ZA (1) | ZA202409847B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2910528T3 (es) | 2014-12-02 | 2022-05-12 | Minerva Neurosciences Inc | Composiciones que comprenden 2-((1-(2(4-fluorofenil)-2-oxoetil)piperidin-4-il)metil)isoindolin-1-ona para tratar la esquizofrenia |
| IL308650B2 (en) | 2017-06-21 | 2025-08-01 | Minerva Neurosciences Inc | Gastro-resistant controlled release oral dosage forms |
| KR102886241B1 (ko) | 2018-08-21 | 2025-11-14 | 미쓰비시 타나베 파마 코퍼레이션 | 음성 증상 및 장애를 치료하고, 신경가소성을 증가시키고, 신경보호를 촉진시키기 위한 롤루페리돈의 용도 |
| IT201800011125A1 (it) * | 2018-12-14 | 2020-06-14 | Dpl Pharma S P A | Composizioni farmaceutiche orali solide comprendenti matrici monolitiche complesse per la somministrazione cronotropica di medicamenti nel tratto gastroenterico |
| JP2025505261A (ja) | 2022-02-14 | 2025-02-21 | ミネルヴァ ニューロサイエンシズ，インコーポレーテッド | 統合失調症患者における再発の予防におけるロルペリドンの使用 |
| WO2025090588A1 (en) | 2023-10-24 | 2025-05-01 | Minerva Neurosciences, Inc. | Roluperidone for the treatment of lysosomal storage disorders and their symptoms |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0325063B1 (en) | 1988-01-21 | 1994-03-09 | Merrell Dow Pharmaceuticals Inc. | Use of 1,4-disubstituted-piperidinyl compounds in the manufacture of a medicament for the treatment of insomnia |
| EP0497843A4 (en) | 1989-10-27 | 1992-09-23 | The Du Pont Merck Pharmaceutical Company | (n-phthalimidoalkyl) piperidines |
| NZ251610A (en) | 1992-04-23 | 1996-02-27 | Merrell Dow Pharma | 4-imidomethyl-1-(2-phenyl-2-oxoethyl)piperidine derivatives and pharmaceutical compositions |
| NZ521576A (en) | 2000-02-29 | 2005-06-24 | Mitsubishi Pharma Corp | Novel cyclic amide derivatives |
| AU2357202A (en) | 2000-09-29 | 2002-04-08 | Solvay Pharm Bv | Ion-strength independent sustained release pharmaceutical formulation |
| TW200517106A (en) | 2003-10-29 | 2005-06-01 | Wyeth Corp | Sustained release pharmaceutical compositions |
| MY147202A (en) * | 2003-11-26 | 2012-11-14 | Novartis Ag | Compositions comprising organic compounds |
| TW200616608A (en) | 2004-07-09 | 2006-06-01 | Forest Laboratories | Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients |
| PE20061490A1 (es) | 2005-06-06 | 2007-02-09 | Merck Sharp & Dohme | Derivados de ciclohexanosulfonilo como inhibidores del transportador de glicina glyt1 |
| US20090088449A1 (en) | 2006-02-07 | 2009-04-02 | Mitsubishi Tanabe Pharma Corporation | 4-acylaminopyridine derivative mediated neurogenesis |
| CA2569776A1 (en) | 2006-02-17 | 2007-08-17 | Kos Life Sciences, Inc. | Low flush niacin formulation |
| TW200817400A (en) | 2006-05-30 | 2008-04-16 | Elbion Ag | Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
| KR20080089279A (ko) | 2007-03-30 | 2008-10-06 | 미쓰비시 타나베 파마 코퍼레이션 | 우울증의 예방 및/또는 치료제 |
| GB2462611A (en) | 2008-08-12 | 2010-02-17 | Cambridge Lab | Pharmaceutical composition comprising tetrabenazine |
| EP2246331A1 (en) | 2009-04-24 | 2010-11-03 | Westfälische Wilhelms-Universität Münster | NR2B-selective NMDA-receptor antagonists |
| ES2649112T3 (es) * | 2009-05-18 | 2018-01-10 | Sigmoid Pharma Limited | Composición que comprende gotas de aceite |
| AR081935A1 (es) | 2010-06-16 | 2012-10-31 | Teijin Pharma Ltd | Tableta con nucleo recubierto de liberacion controlada |
| WO2012012542A1 (en) | 2010-07-20 | 2012-01-26 | Cyrenaic Pharmaceuticals, Inc. | Methods of use of cyclic amide derivatives to treat schizophrenia |
| US8937900B2 (en) | 2010-07-20 | 2015-01-20 | Qualcomm Incorporated | Enhancing pilot channel transmission in TD-SCDMA multicarrier systems using secondary carrier frequencies |
| CN103108548A (zh) | 2010-07-20 | 2013-05-15 | 昔勒尼药品公司 | 使用环酰胺衍生物治疗σ受体介导的病症的方法 |
| US20120040008A1 (en) | 2010-08-11 | 2012-02-16 | Ashish Chatterji | Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists |
| EP2468264A1 (en) * | 2010-12-27 | 2012-06-27 | Laboratorios Liconsa, S.A. | Oral pharmaceutical tablet for controled release of mesalazine and process for obtaining it |
| US9737531B2 (en) | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
| KR20140045925A (ko) | 2011-03-17 | 2014-04-17 | 루핀 리미티드 | 선택적 세로토닌 재흡수 억제제의 방출조절형 약제학적 조성물 |
| CN104023725B (zh) * | 2011-08-16 | 2019-04-26 | 卡迪欧拉有限公司 | 控释制剂 |
| AU2014239883B2 (en) * | 2013-03-14 | 2019-01-17 | Therabiome, Llc | Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents |
| CN104586771B (zh) * | 2013-10-30 | 2018-01-16 | 广州朗圣药业有限公司 | 一种盐酸坦洛新缓释微丸制剂 |
| CN106687462A (zh) | 2014-04-30 | 2017-05-17 | 因赛特公司 | Jak1抑制剂的制备方法以及其新形式 |
| EP3144308B1 (en) | 2014-05-16 | 2020-06-24 | Takeda Pharmaceutical Company Limited | Nitrogen-containing heterocyclic compound |
| WO2015191554A1 (en) | 2014-06-09 | 2015-12-17 | Intra-Cellular Therapies, Inc. | Compounds and methods of use to treat schizophrenia |
| RU2697851C2 (ru) * | 2014-08-13 | 2019-08-21 | Седарс-Синаи Медикал Сентер | Антиметаногенные композиции и их применение |
| ES2910528T3 (es) | 2014-12-02 | 2022-05-12 | Minerva Neurosciences Inc | Composiciones que comprenden 2-((1-(2(4-fluorofenil)-2-oxoetil)piperidin-4-il)metil)isoindolin-1-ona para tratar la esquizofrenia |
| JP6855469B2 (ja) * | 2015-10-16 | 2021-04-07 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 消化器標的療法のための処方物を調製するための工程 |
| SG11201810358YA (en) | 2016-05-25 | 2018-12-28 | Mitsubishi Tanabe Pharma Corp | Compositions and methods for treating negative symptoms in non-schizophrenic patients |
| IL308650B2 (en) | 2017-06-21 | 2025-08-01 | Minerva Neurosciences Inc | Gastro-resistant controlled release oral dosage forms |
| KR102886241B1 (ko) | 2018-08-21 | 2025-11-14 | 미쓰비시 타나베 파마 코퍼레이션 | 음성 증상 및 장애를 치료하고, 신경가소성을 증가시키고, 신경보호를 촉진시키기 위한 롤루페리돈의 용도 |
| EP3990113A1 (en) | 2019-06-28 | 2022-05-04 | Teva Czech Industries s.r.o. | Solid state forms of roluperidone and salts thereof |
| JP2025505261A (ja) | 2022-02-14 | 2025-02-21 | ミネルヴァ ニューロサイエンシズ，インコーポレーテッド | 統合失調症患者における再発の予防におけるロルペリドンの使用 |
-
2018
- 2018-06-21 IL IL308650A patent/IL308650B2/en unknown
- 2018-06-21 CN CN201880054407.9A patent/CN111511353A/zh active Pending
- 2018-06-21 UA UAA202000290A patent/UA127349C2/uk unknown
- 2018-06-21 NZ NZ760127A patent/NZ760127A/en unknown
- 2018-06-21 IL IL271606A patent/IL271606B2/en unknown
- 2018-06-21 BR BR112019027398-0A patent/BR112019027398A2/pt active IP Right Grant
- 2018-06-21 JP JP2019570906A patent/JP2020525436A/ja active Pending
- 2018-06-21 US US16/015,151 patent/US11464744B2/en active Active
- 2018-06-21 WO PCT/US2018/038853 patent/WO2018237207A1/en not_active Ceased
- 2018-06-21 AU AU2018290287A patent/AU2018290287B2/en active Active
- 2018-06-21 CA CA3067031A patent/CA3067031A1/en active Pending
- 2018-06-21 PE PE2019002573A patent/PE20200732A1/es unknown
- 2018-06-21 IL IL319156A patent/IL319156A/en unknown
- 2018-06-21 EP EP18740435.5A patent/EP3641732A1/en active Pending
-
2019
- 2019-12-18 MX MX2023002994A patent/MX2023002994A/es unknown
- 2019-12-18 CL CL2019003743A patent/CL2019003743A1/es unknown
- 2019-12-20 CO CONC2019/0014496A patent/CO2019014496A2/es unknown
-
2022
- 2022-06-15 US US17/841,284 patent/US12048768B2/en active Active
-
2023
- 2023-09-12 JP JP2023147484A patent/JP2023175778A/ja active Pending
-
2024
- 2024-06-10 US US18/738,782 patent/US20250009665A1/en active Pending
- 2024-09-13 AU AU2024219717A patent/AU2024219717A1/en active Pending
- 2024-12-19 ZA ZA2024/09847A patent/ZA202409847B/en unknown
-
2025
- 2025-06-17 JP JP2025101290A patent/JP2025134828A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020525436A5 (https=) | ||
| JP6084161B2 (ja) | ７−［４−（４−ベンゾ［ｂ］チオフェン−４−イル−ピペラジン−１−イル）ブトキシ］−１Ｈ−キノリン−２−オン又はその塩を含む錠剤 | |
| FI117961B (fi) | Nopeasti vaikutuksen aloittava formulaatio | |
| CN110035757A (zh) | 一种奥拉帕尼口服缓控释药物组合物及其用途 | |
| JP2015506377A5 (https=) | ||
| JP2011513391A (ja) | ミコフェノラートを含有する徐放性医薬組成物およびその方法 | |
| CN105142618A (zh) | 提供药理及临床效应的莫沙必利每日单次施用缓释制剂 | |
| JP2016516698A5 (https=) | ||
| JP2014501267A (ja) | メサラジン制御放出用の経口用医薬錠剤および前記錠剤を得るための製法 | |
| JP2015510916A5 (https=) | ||
| JP2013529665A5 (https=) | ||
| WO2014029953A1 (en) | Hot melt extruded (hme) pharmaceutical composition of cinacalcet | |
| AU2014279743B2 (en) | Modified release formulation | |
| WO2013084089A1 (en) | Methods for treating cardiovascular disorder | |
| CN101431992A (zh) | 包含尼美舒利的新型低剂量药物组合物及其制备和用途 | |
| JP2016530238A5 (https=) | ||
| JP2023026417A (ja) | フマル酸ジメチルを含有する腸溶性錠剤 | |
| JP2010538062A5 (https=) | ||
| CN110035751A (zh) | 一种维利帕尼缓控释药物组合物及其用途 | |
| JP2015120758A5 (https=) | ||
| WO2022138717A1 (ja) | 経口固形製剤 | |
| JP6854162B2 (ja) | 錠剤 | |
| JP6815109B2 (ja) | デュロキセチンまたは薬学的に許容されるその塩を有効成分とする医薬組成物 | |
| CA2854612C (en) | Delivery systems for improving oral bioavailability of fenobam, its hydrates, and salts | |
| EP3439638A1 (en) | Pharmaceutical composition comprising an atypical antipsychotic agent and method for the preparation thereof |